Pharmacokinetic study of esomeprazole in patients with hepatic impairment
Henrik Sjövall(Sahlgrenska University Hospital), Mohammed Hassan‐Alin(AstraZeneca (United Kingdom)), Kerstin Röhss(AstraZeneca (Sweden)), Johan Holmberg(University of California, Los Angeles), Einar S. Björnsson(Sahlgrenska University Hospital), Göran Hasselgren(AstraZeneca (Sweden))
Cited by 36
Related Papers
Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazole
|Alimentary Pharmacology & Therapeutics|2001|175
Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
|European Journal of Clinical Pharmacology|2000|140
Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole
|British Journal of Clinical Pharmacology|1998|124
Glioma-induced inhibition of caspase-3 in microglia promotes a tumor-supportive phenotype
|Nature Immunology|2016|104